Immunotherapies that mobilize a patient’s own immune system to fight cancer have become a treatment pillar. These therapies, including CAR T-cell therapy, have performed well in cancers like leukemias and lymphomas, but the results have been less promising in solid tumors.
FDA rejects Alnylam’s heart disease treatment over insufficient data
The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the
October 9, 2023